Results 181 to 190 of about 22,485 (236)

Posterior Uveitis

2010
Posterior uveitis is a major cause of ocular morbidity worldwide. Systemic corticosteroids (CS) remain the primary method of treatment for noninfectious posterior uveitis; however, CS are associated with many side effects. Immunomodulatory therapy (IMT) is recommended when inflammatory control is not attained with a tolerable level of systemic CS (
Harvey Siy, Uy, Ellen, Yu-Keh, Pik Sha, Chan   +2 more
openaire   +2 more sources

Tuberkuloseassoziierte Uveitis posterior

Der Ophthalmologe, 2010
The commercially available interferon gamma release assays T-SPOT.TB and QuantiFERON-TB Gold/QuantiFERON-TB Gold In-Tube may be important, besides the direct detection with culturing, PCR or the Mantoux skin test, for the diagnosis of tuberculosis as a possible cause of uveitis.
N. Negraszus, U. Pleyer
openaire   +1 more source

Posterior Uveitis Associated with Cemiplimab

Ocular Immunology and Inflammation, 2021
The immune checkpoint inhibitors (ICPIs) comprise a class of oncologic immunotherapies. The most recent US Food and Drug Administration-approved ICPI is cemiplimab (Libtayo®). Cemiplimab, like the other ICPIs, blocks checkpoint receptors in order to disinhibit T-cells so that they may detect and eliminate tumor cells. Consequently, treatment with ICPIs
Eliot R. Dow, Kirk Hou, Susan Ransome, Sam Abbassi, Edmund Tsui   +4 more
openaire   +2 more sources

Noninfectious Posterior Uveitis

Seminars in Ophthalmology, 1996
Posterior uveitis encompasses a broad range of clinical entities with multiple manifestations. A complete history and physical examination provide diagnostic clues and guide an appropriate laboratory evaluation. An infectious cause should always be considered before instituting therapy.
Jonathan D. Walker, E. Mitchel Opremcak
openaire   +1 more source

Posterior uveitis in Hodgkin’s disease

Australian and New Zealand Journal of Ophthalmology, 1999
Purpose: To describe the features of posterior uveitis in patients who either developed or were known to have, biopsy‐proven Hodgkin’s disease (HD). Methods: Four patients were identified who were attending the uveitis clinic. Their charts were reviewed retrospectively and information on their HD was obtained from other hospitals where necessary ...
H, Towler, M, de la Fuente, S, Lightman
openaire   +2 more sources

Intermediate and Posterior Uveitis

2007
Sight-threatening intraocular inflammation affecting the posterior segment of the eye may be predominantly located in the peripheral retina and vitreous (intermediate uveitis) or postequatorially where it manifests as inflammation of the retina, retinal vessels and/or optic nerve with cellular infiltration of the choroid and retina and edema ...
openaire   +2 more sources

Imaging techniques for posterior uveitis

Current Opinion in Ophthalmology, 2004
The goal of this review is to describe the more commonly used imaging techniques and their use to identify causes of vision loss, extent of disease, and distinctive patterns associated with various causes of posterior uveitis.Distinctive patterns seen with new imaging techniques and applications are being described.
Antonio P, Ciardella, F Ryan, Prall, N, Borodoker, Emmett T, Cunningham   +3 more
openaire   +2 more sources

Infectious causes of posterior uveitis

Canadian Journal of Ophthalmology, 2013
The differential diagnosis of posterior infectious uveitis is broad. There are, however, a few common infectious causes of posterior uveitis that should always be considered. The more common infectious causes of posterior uveitis include syphilis, toxoplasmosis, tuberculosis, endogenous endophthalmitis, and viral causes (including herpes simplex virus,
openaire   +2 more sources

Systemic Management of Posterior Uveitis

Journal of Ocular Pharmacology and Therapeutics, 2003
In the treatment of uveitis, corticosteroids are usually included in first-line therapy due to its rapid onset of action and excellent safety profile. Systemic immunosuppressive agents also play an important role in the management of posterior uveitis.
openaire   +2 more sources

Alirocumab-associated unilateral posterior uveitis

BMJ Case Reports
A man in his mid-40s who had been recently started on alirocumab (a human monoclonal antibody which inhibits proprotein convertase subtilisin/kexin type 9) due to his strong familial cardiovascular risk and refractory hypercholesterolaemia presented with a few-hour history of acute-onset left-sided blurred vision.
Ehinomen Sarah Inegbedion, Matthew Azzopardi, Tracey Inessa, Yu Jeat Chong   +3 more
openaire   +2 more sources